PSMA radioligand PET/CT showed comparable performances in high-grade gliomas when compared with MRI [32,34,36] and was superior to 18F-FDG PET both in staging and restaging gliomas mainly due to the absence of the high physiologic background in normal brain parenchyma in 18F-FDG PET/CT exams. The gene discussed is FOLH1; the disease is central nervous system cancer.